In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
400 News Items found
Leiomyosarcoma expert Martee Hensley
In the Clinic
What’s New in Leiomyosarcoma?

In this Q&A, medical oncologist Martee Hensley discusses the diagnosis and treatment of leiomyosarcoma and other uterine sarcomas.
Rihanna sitting in a chair outside
Feature
Getting to the Root of Pediatric Cancers

MSK Kids is leading a major effort to fully deliver on the promise of precision medicine for our youngest patients.
Fluorescent image of CAR T cells in mouse liver fibrosis
In the Lab
A New Target for CAR T Cells: Senescence-Related Diseases

From atherosclerosis and diabetes to liver fibrosis and osteoarthritis, senescent cells are at the root of many debilitating diseases. Scientists increasingly have them in the crosshairs.
Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in JAMA Oncology.
GSK Dean Michael Overholtzer stands at the podium
Event
Virtual Convocation and Commencement Ceremony Honors Graduates and Award Winners

Memorial Sloan Kettering’s 42nd annual ceremony recognized graduates and award winners with a virtual ceremony.
Announcement
7 Gerstner Sloan Kettering Students Prepare to Graduate

Seven students will be awarded PhD degrees on May 19, 2021, from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK), an innovative doctoral program that prepares the next generation of basic laboratory scientists to work in research areas related to human disease with a focus on cancer.
Close up of an MSK researcher's hands and arms handling test tubes in the lab.
Gerstner Sloan Kettering Graduate Students Receive 2024-2025 Fellowships

Nine GSK PhD students were awarded competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science Foundation (NSF).
Dr. Sandra D'Angelo
In the Clinic
FDA Grants Full Approval to Engineered Cell Therapy for Treating Rare Sarcoma

The FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.
Close up of gloved hands working in a lab
MSK Research Highlights September 29, 2023

New research from MSK develops a method for analyzing cancer cells that survive treatment for acute myeloid leukemia; identifies a transcription factor that orchestrates natural killer cell response; and finds vepafestinib is a promising therapeutic for the treatment of RET-driven cancers.
New Study Looks at Low-Dose Radiation That Could Make CAR T Cell Therapy More Effective

A preclinical study published in the journal Molecular Therapy by researchers at Memorial Sloan Kettering (MSK) provides evidence that radiation therapy could improve the efficacy of CAR T cell therapy for solid tumors.